Welcome to our dedicated page for Salarius Pharmaceuticals news (Ticker: SLRX), a resource for investors and traders seeking the latest updates and insights on Salarius Pharmaceuticals stock.
Salarius Pharmaceuticals Inc (NASDAQ: SLRX) is a clinical-stage biotechnology company pioneering targeted therapies for cancers with high unmet medical needs. This page serves as the definitive source for verified news and official updates, providing stakeholders with timely insights into the company's progress in oncology drug development.
Investors and researchers will find curated press releases covering clinical trial milestones, regulatory developments, and strategic partnerships. Key focus areas include updates on Salarius' protein degradation therapies and inhibitor candidates, financial disclosures, and collaborative research initiatives in precision medicine.
All content is rigorously sourced from SEC filings, corporate communications, and validated industry reports. The repository is maintained to support informed analysis while adhering to financial compliance standards. Bookmark this page for efficient tracking of SLRX's advancements in addressing gene dysregulation through innovative biopharmaceutical approaches.
Salarius Pharmaceuticals (NASDAQ: SLRX) announced significant preclinical findings for its novel molecular glue, SP-3164, demonstrating strong antitumor activity in models of follicular lymphoma and multiple myeloma. During the American Association for Cancer Research (AACR) Annual Meeting, two posters were presented highlighting SP-3164’s efficacy both as a single agent and in combination with established treatments such as venetoclax and bortezomib. The research showcased that SP-3164 induced apoptosis in multiple myeloma cell lines and exhibited superior activity compared to other existing therapies. This progress supports Salarius’ strategy for advancing SP-3164 in hematologic cancers as it moves closer to clinical trials planned for 2023.
FAQ
What is the current stock price of Salarius Pharmaceuticals (SLRX)?
What is the market cap of Salarius Pharmaceuticals (SLRX)?
